Reuters: Eli Lilly antibody trial paused due to potential safety concern
U.S. drugmaker Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.
This is a similar antibody treatment to Regeneron, one that Donald Trump said “cured” him. There are no details about how what the safety concern is or how many volunteers were impacted.
